Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006–2015
Background: Herpes zoster (HZ), or shingles, is caused by reactivation of varicella-zoster virus in latently infected individuals. Live-attenuated HZ vaccine (zoster vaccine live, ZVL) is approved in the United States for persons aged ≥50 years and recommended by the CDC for persons ≥60 years. Metho...
Main Authors: | Elaine R. Miller, Paige Lewis, Tom T. Shimabukuro, John Su, Pedro Moro, Emily Jane Woo, Christopher Jankosky, Maria Cano |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-08-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2018.1456598 |
Similar Items
-
A post hoc analysis utilizing the FDA toxicity grading scale to assess injection site adverse events following immunization with the live attenuated Zoster Vaccine (ZVL)
by: Zoran Popmihajlov, et al.
Published: (2018-12-01) -
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
by: Yasmin Marra, et al.
Published: (2022-11-01) -
Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine
by: John Litt, et al.
Published: (2020-12-01) -
The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study
by: Alessia Melegaro, et al.
Published: (2018-07-01) -
Rhabdomyolysis after recombinant zoster vaccination: a rare adverse reaction
by: Nishan Rajaratnam, et al.
Published: (2021-01-01)